logo BDSP

Base documentaire


  1. Economic comparison of nimesulide and diclofenac, and the incidence of adverse events in the treatment of rheumatic disease in Greece.

    Article, Communication - En anglais

    EULAR'98 Nimesulide Satellite Symposium. Geneva, CHE, 1998/09/07.

    In Greece a 15-day treatment of rheumatic disease with diclofenac costs 56% more than treatment with nimesulide.

    This is due to the lower incidence of gastrointestinal adverse events with nimesulide, and the absence of serious gastrointestinal complications leading to hospitalization, which more than offset the higher acquisition cost of nimesulide.

    The average saving by using nimesulide instead of diclofenac is about US$21 per patient for a 15-day treatment period.

    Mots-clés Pascal : Système ostéoarticulaire pathologie, Rhumatologie, Traitement, Nimésulide, Etude comparative, Chimiothérapie, Diclofénac, Homme, Analyse coût, Epidémiologie, Incidence, Toxicité, Gastrointestinal, Grèce, Europe, Antiinflammatoire non stéroïde, Arylacétique acide dérivé

    Mots-clés Pascal anglais : Diseases of the osteoarticular system, Rheumatology, Treatment, Nimesulide, Comparative study, Chemotherapy, Diclofenac, Human, Cost analysis, Epidemiology, Incidence, Toxicity, Gastrointestinal, Greece, Europe, Non steroidal antiinflammatory agent, Arylacetic acid derivatives

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0319206

    Code Inist : 002B02L. Création : 16/11/1999.